Immunotherapy for prostate cancer - patient education video

In a bit of a temporary departure from our focus on clinical trials, we thought we would share our latest patient education videos for prostate cancer patients.  Here Dr. Beer discusses immunotherapy for prostate cancer - very much the way it would be discussed in a clinic visit.  In the coming weeks, we will share our videos on chemotherapy and hormonal therapy for prostate cancer patients.

To put a smile on your face see Larry's latest cartoon.
To learn more about clinical trials, take a look at our book.

(c) 2012 Tom Beer and Larry Axmaker

More Cancer Vaccines on the Horizon

We already discussed the first FDA approved cancer vaccine, Provenge^©, an individualized treatment for metastatic (late stage) prostate cancer. The Journal of the National Cancer Institute recently published an article explaining the process of developing new cancer vaccines. According to the National Cancer Institute there are currently nine phase III clinical trials and 64 phase II clinical trials testing cancer vaccines. Cancer vaccines are developed to treat cancer—they’re not preventive.

The problem in developing vaccines has been to find a way to stimulate the body’s immune system to fight cancer. Cancer cells produce antigens which in turn trigger an immune response—often too weak to kill or weaken the cancer cells. NCI researchers are studying numerous ways to make it easier for your immune system to identify and mount a stronger response to destroy cancer cells. Cancer treatment vaccines have two goals. First, they must stimulate specific immune responses against the correct target. Second, the immune response must be strong enough to overcome the barriers that cancer cells use to protect themselves.

Vaccines were first tested on patients with late stage cancer who had suppressed (weakened) immune systems. Some current trials focus on patients with earlier stage cancers and stronger immune systems. Vaccines may work better when combined with standard treatments including chemotherapy and radiation.

Are you interested in a cancer clinical trial using a cancer vaccine? Go to the NCI clinical trials database and check out your type of cancer and see what clinical trials are available. Vaccines have the added benefit of minimal toxic side effects.

Want to know more about cancer vaccines? The NCI has an extensive Cancer Vaccine Fact Sheet online.

To put a smile on your face see Larry's latest cartoon


(c) 2012 Tom Beer and Larry Axmaker

The big trends in medical treatments for cancer

Medications are the mainstay of treatment for those cancers that by their nature or because they have spread, cannot be removed surgically or eliminated with radiation.  Medical treatments are also often added to surgery or radiation to kill the few cancer cells that may have escaped and reduce the chance of cancer coming back.  The broad trends that are driving research into new medications for cancer include:

·        New chemotherapy drugs and combinations of drugs

·        New ways to manipulate the hormones that drive certain cancers (primarily breast and prostate cancer)

·        More specific and targeted therapies that are sometimes referred to as “smart bombs.”  These types of treatments are designed to attack very specific mechanisms that drive cancer growth and spread.  A variety of technologies make targeted therapy possible.  Some are artificial antibodies, synthetic small chemical molecules, and gene-directed therapies

·        Harnessing the immune system to fight cancer

·        All cancer therapy is likely to become more personalized (individualized) with treatments selected to match each person’s unique cancer.  

New Phase III Cancer Clinical Trials - December 2011

     Our search, carried out on December 22, showed 22 new phase III trials registered in the last 30 days.  We will highlight two that explore immunotherapy in two very different contexts.  
     The first trial compares the use of the patient's own stimulated killer cells (a part of one's natural immune system) to the use of chemotherapy in advanced lung cancer.  The study is being carried out in China, so it is likely inaccessible to most US cancer patients, but it is a good example of how immunotherapy continues to be a major direction for cancer clinical trials.  
     The second trial tests a vaccine product called NeuVax (TM) to determine if the vaccine can prevent the relapse of breast cancer.  Patients who have early stage node positive breast cancer that has low or intermediate expression of the HER2 protein are eligible.  Experimental treatment follows the completion of standard treatments such as surgery, radiation, and chemotherapy.

     You can click on the hyperlinks above to see each individual trial or click here to learn more about both of them:

New immunotherapy trials Dec 2011 (click here - link expires March 21, 2012)
     To see all 22 new phase III trials registered in the last 30 days, click here:
All new phase III cancer trials Dec 2011 (click here - link expires March 21, 2012)